

New Bio-Facilities Planned

Biogen invested USD \$1.2 BIL last July into a new production plant in Luterbach, Switzerland as part of its plan to bolster its current drug supply network to meet future demand. The co. recently announced it will equip its new Swiss biomanufacturing plant with eight 18,000L stainless steel bioreactors supplied by ABEC, and expects to begin commercial production in early 2019. *Source: Bio-Pharma Reporter, March 2016.*

Boehringer-Ingelheim is building a new large-scale biopharma production facility in Vienna to produce active ingredients using cell cultures. Details are still sketchy, but the co. looks to spend approx. USD \$550 MIL, add about 400 jobs, and will be open in 2021. The co. will transfer cell-culture operations to Vienna over the next few years. *Source: PR Release, Dec 2015*

Ajinomoto Althea, Inc. will expand its existing biological drug product manufacturing operations to include highly active materials including Antibody Drug Conjugates (ADCs). The new facility will be located close to existing Althea operations in San Diego, California, U.S. *Source: PR Newswire, Dec 2015*

Repligen recently paid USD \$22.5MIL for German-based Atoll, which makes a range of pre-packed chromatography columns. *Source: Various, April 2016*

Aurobindo, an Indian generic drugmaker, will build its new headquarters for U.S. operations and manufacturing in Durham, North Carolina, bringing \$31.7 million in investments and creating 275 jobs. *Source: Triangle Business Journal, April 2016*

New Facilities

The Maryland Commerce Department approved a USD \$50,000 conditional loan for BioFactura's expansion in Frederick, Maryland, U.S. The loan will

convert to a grant if the co. invests at least \$450,000 in the new facility by December, retains existing employees and reaches employment of at least 30 by Dec. 31, 2020. *Source: The Eagle.com, March 2016*

Aptuit, LLC acquired Swiss-based Exquiron Biotech AG, a leading CRO for early phase drug discovery, for outsourced discovery services. *Source: Pharma Outsourcing, April 2016*

Brammer Biopharmaceuticals will merge with Florida Biologix to create the best-in-class cell and gene therapy biologics contract development and manufacturing organization (CDMO). Brammer currently occupies 45,000 sq. ft. of PD and Phase I/II clinical manufacturing space in Alachua, Florida, U.S., and is developing a 50,000 sq. ft. facility in Lexington, Massachusetts, U.S. *Source: PR Newswire, March 2016*

CMC Biologics A/S and **IDT Biologika GmbH** will partner to offer drugmakers an antibody drug conjugate manufacturing service. CMC will provide PD and bulk antibody manufacturing services, while IDT will focus on the conjugation, and also handle fill finish and packaging. Both companies hope this will provide drug industry customers with a faster means of making ADC for clinical trials and commercial launch. *Source: Outsourcing-Pharma, Feb 2016*

BioINNOVATIONS

Patheon will provide manufacturing solutions to Amgen through its “flexible manufacturing offerings” and dependent on what Amgen needs. *Source: Fierce Pharma, March 2016*

Wrap-up BioNEWS

Biovest International Singapore created a new subsidiary, Cell Culture Company that will supply automated single-use perfusion bioreactor systems and custom mammalian cell and protein manufacturing services to the diagnostic, therapeutic, and animal healthcare industries. Biovest will

continue its commercialization of personalized immunotherapies. *Source: BioSpectrum Asia, March 2016*

BioFactura, Inc., recently closed a USD \$1.8MIL Series A round of financing, an oversubscription of the original \$1.5M target. The funds will be used to advance a portfolio of biosimilars to the advanced preclinical stages. *Source: PR Release, April 2016*

Bayer recently established the Bayer East Coast Innovation Center in Cambridge, Massachusetts, U.S., and is similar to other Bayer centers established in San Francisco, Berlin, Beijing, Osaka and Singapore. The new center will "enable Bayer's teams to deepen relationships and opportunities to influence the discovery and development of new therapeutics. *Source: Various, March 2016*

Charles River Labs recently completed a USD \$585 MIL buyout of WIL Research, which currently is focused on drug safety studies and contract development and manufacturing services. WIL Research employs about 1,300 people in the U.S., Europe and Japan. *Source: Fierce Pharma, January 2016*